# Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients

> **NCT01973842** · PHASE2 · UNKNOWN · sponsor: **Aristotle University Of Thessaloniki** · enrollment: 90 (estimated)

## Conditions studied

- Subfertility

## Interventions

- **DRUG:** 0.1 mg triptorelin
- **DRUG:** 0.2 mg triptorelin
- **DRUG:** 0.4 mg triptorelin

## Key facts

- **NCT ID:** NCT01973842
- **Lead sponsor:** Aristotle University Of Thessaloniki
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-02
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2016-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01973842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01973842, "Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01973842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*